{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:46:05Z","timestamp":1769834765175,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00700-1","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:24:29Z","timestamp":1767021869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluations of Glecaprevir\/Pibrentasvir and Grazoprevir\/Elbasvir for the treatment of hepatitis C: a systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Mojtaba","family":"Jafari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Teymourzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Salesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khosro","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Abyazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Heiat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"7","key":"700_CR1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrmicro3046","volume":"11","author":"R Bartenschlager","year":"2013","unstructured":"Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482\u201396.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"700_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bpg.2012.09.012","volume":"26","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol. 2012;26(4):371\u201380.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"700_CR3","doi-asserted-by":"publisher","first-page":"e11879","DOI":"10.5812\/hepatmon.11879","volume":"14","author":"MS Afzal","year":"2014","unstructured":"Afzal MS, Anjum S, Zaidi NU. Changing of HCV clade pattern in iran; the possible means for something good. Hepat Mon. 2014;14(1):e11879.","journal-title":"Hepat Mon"},{"issue":"1","key":"700_CR4","first-page":"41","volume":"6","author":"A Tamaddoni","year":"2007","unstructured":"Tamaddoni A, Mohammadzadeh I, Ziaei O. Seroprevalence of HCV antibody among patients with beta-thalassemia major in Amirkola thalassemia Center, Iran. Iran J Allergy Asthma Immunol. 2007;6(1):41.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"700_CR5","first-page":"47","volume":"4","author":"SM Alavian","year":"2009","unstructured":"Alavian SM. Hepatitis C infection in Iran; A review Article. Arch Clin Infect Dis. 2009;4(1):47\u201359.","journal-title":"Arch Clin Infect Dis"},{"issue":"6","key":"700_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","volume":"15","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting antiviral agents for patients with hepatitis C virus genotype 1 infection are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15(6):827\u201337. e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"700_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3111\/13696998.2015.1044457","volume":"18","author":"K Westerhout","year":"2015","unstructured":"Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J. A cost utility analysis of Simeprevir used with peginterferon\u2009+\u2009ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National health service. J Med Econ. 2015;18(10):838\u201349.","journal-title":"J Med Econ"},{"issue":"Suppl 2","key":"700_CR8","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1386-6532(05)80032-0","volume":"34","author":"M Beltran","year":"2005","unstructured":"Beltran M, Navas MC, De la Hoz F, Mercedes Munoz M, Jaramillo S, Estrada C, et al. Hepatitis C virus Seroprevalence in multi-transfused patients in Colombia. J Clin Virol. 2005;34(Suppl 2):S33\u20138.","journal-title":"J Clin Virol"},{"issue":"3","key":"700_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcv.2012.03.002","volume":"54","author":"HA Torres","year":"2012","unstructured":"Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, et al. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol. 2012;54(3):218\u201322.","journal-title":"J Clin Virol"},{"issue":"11","key":"700_CR10","doi-asserted-by":"publisher","first-page":"e37094","DOI":"10.5812\/ircmj.37094","volume":"18","author":"SM Alavian","year":"2016","unstructured":"Alavian SM, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, Rezaei Hemami M, et al. A Cost-Utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iran Red Crescent Med J. 2016;18(11):e37094.","journal-title":"Iran Red Crescent Med J"},{"issue":"13","key":"700_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975\u201382.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"700_CR12","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","volume":"56","author":"C Sarrazin","year":"2012","unstructured":"Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):S88\u2013100.","journal-title":"J Hepatol"},{"issue":"1","key":"700_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/ar700109k","volume":"41","author":"FG Njoroge","year":"2008","unstructured":"Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008;41(1):50\u20139.","journal-title":"Acc Chem Res"},{"issue":"21","key":"700_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG. Therapy of hepatitis C\u2013back to the future. N Engl J Med. 2014;370(21):2043\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"700_CR15","doi-asserted-by":"publisher","first-page":"e25540","DOI":"10.5812\/hepatmon.25540","volume":"14","author":"MA Pourhoseingholi","year":"2014","unstructured":"Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of pegylated interferon and Ribavirin; how much shall pay for Iranian patients? Hepat Mon. 2014;14(11):e25540.","journal-title":"Hepat Mon"},{"issue":"6","key":"700_CR16","doi-asserted-by":"publisher","first-page":"e0157098","DOI":"10.1371\/journal.pone.0157098","volume":"11","author":"N Vernaz","year":"2016","unstructured":"Vernaz N, Girardin F, Goossens N, Br\u00fcgger U, Riguzzi M, Perrier A, et al. Drug pricing evolution in hepatitis C. PLoS ONE. 2016;11(6):e0157098.","journal-title":"PLoS ONE"},{"key":"700_CR17","first-page":"5","volume":"4","author":"JM Pawlotsky","year":"2012","unstructured":"Pawlotsky JM. New antiviral agents for hepatitis C. F1000. Biol Rep. 2012;4:5.","journal-title":"Biol Rep"},{"issue":"3","key":"700_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jare.2014.11.004","volume":"6","author":"T Elbaz","year":"2015","unstructured":"Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015;6(3):301\u201310.","journal-title":"J Adv Res"},{"issue":"9","key":"700_CR19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","volume":"23","author":"OT Due","year":"2020","unstructured":"Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, et al. Cost-Utility analysis of Direct-Acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2020;23(9):1180\u201390.","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"6","key":"700_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with Sofosbuvir and Ledipasvir in the united States. Ann Intern Med. 2015;162(6):397\u2013406.","journal-title":"Ann Intern Med"},{"issue":"2","key":"700_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013;158(2):114\u201323.","journal-title":"Ann Intern Med"},{"issue":"4","key":"700_CR22","doi-asserted-by":"publisher","first-page":"e0248748","DOI":"10.1371\/journal.pone.0248748","volume":"16","author":"R Suenaga","year":"2021","unstructured":"Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a treat-all strategy using Direct-Acting antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS ONE. 2021;16(4):e0248748.","journal-title":"PLoS ONE"},{"issue":"4","key":"700_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3851\/IMP3290","volume":"24","author":"L Szilberhorn","year":"2019","unstructured":"Szilberhorn L, Kalo Z, Agh T. Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review. Antivir Ther. 2019;24(4):247\u201359.","journal-title":"Antivir Ther"},{"issue":"1","key":"700_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","volume":"37","author":"I Kawaguchi","year":"2020","unstructured":"Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, et al. A Cost-Effectiveness analysis of Glecaprevir\/Pibrentasvir versus existing Direct-Acting antivirals to treat chronic hepatitis C in Japan. Adv Therapy. 2020;37(1):457\u201376.","journal-title":"Adv Therapy"},{"key":"700_CR25","doi-asserted-by":"publisher","first-page":"836986","DOI":"10.3389\/fpubh.2022.836986","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Guo M, Ke L, You R. Cost-Effectiveness of Elbasvir\/Grazoprevir for the treatment of chronic hepatitis C: A systematic review. Front Public Health. 2022;10:836986.","journal-title":"Front Public Health"},{"key":"700_CR26","unstructured":"EPPI-Centre, UCL Social Research Institute. EPPI-Centre Cost Converter. Available from: https:\/\/eppi.ioe.ac.uk\/costconversion\/default.aspx. [Accessed September 18, 2025]."},{"issue":"3","key":"700_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The use of Cost-Effectiveness thresholds for evaluating health interventions in Low- and Middle-Income countries from 2015 to 2020: A review. Value Health. 2022;25(3):385\u20139.","journal-title":"Value Health"},{"issue":"4","key":"700_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","volume":"23","author":"D Cai","year":"2022","unstructured":"Cai D, Shi S, Jiang S, Si L, Wu J, Jiang Y. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607\u201315.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"700_CR29","doi-asserted-by":"publisher","first-page":"e0266934","DOI":"10.1371\/journal.pone.0266934","volume":"17","author":"H Iino","year":"2022","unstructured":"Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLoS ONE. 2022;17(4):e0266934.","journal-title":"PLoS ONE"},{"issue":"7","key":"700_CR30","doi-asserted-by":"publisher","first-page":"A731","DOI":"10.1016\/j.jval.2016.09.2202","volume":"19","author":"J Shafrin","year":"2016","unstructured":"Shafrin J, May SG, Skornicki M, Hathway J, Macaulay R, Villeneuve J, et al. Use of net monetary benefit analysis to comprehensively understand the value of innovative treatments. Value Health. 2016;19(7):A731.","journal-title":"Value Health"},{"issue":"1","key":"700_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12874-023-01956-y","volume":"23","author":"L Everest","year":"2023","unstructured":"Everest L, Chen BE, Hay AE, Cheung MC, Chan KKW. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian cancer trials group. BMC Med Res Methodol. 2023;23(1):179.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"700_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00019053-200321010-00003","volume":"21","author":"N Zethraeus","year":"2003","unstructured":"Zethraeus N, Johannesson M, J\u00f6nsson B, L\u00f6thgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. PharmacoEconomics. 2003;21(1):39\u201348.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"700_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40258-020-00623-3","volume":"19","author":"P Chen","year":"2021","unstructured":"Chen P, Jin M, Cao Y, Li H. Cost-Effectiveness analysis of oral Direct-Acting antivirals for Chinese patients with chronic hepatitis C. Appl Health Econ Health Policy. 2021;19(3):371\u201387.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"700_CR34","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10620-020-06281-8","volume":"66","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, et al. Cost-Utility of All-Oral Direct-Acting antiviral regimens for the treatment of genotype 1 chronic hepatitis C Virus-Infected patients in Hong Kong. Dig Dis Sci. 2021;66(4):1315\u201326.","journal-title":"Dig Dis Sci"},{"key":"700_CR35","unstructured":"CHEN C, AI D, LU Y. Cost-effectiveness analysis of glecaprevir\/pibrentasvir versus elbasvir\/grazoprevir in chronic hepatitis C genotype 1b treatment-naive patients without cirrhosis. China Pharm. 2020:1113\u20138."},{"key":"700_CR36","doi-asserted-by":"publisher","first-page":"e20190594","DOI":"10.1590\/0037-8682-0594-2019","volume":"53","author":"VL Ferreira","year":"2020","unstructured":"Ferreira VL, Leonart LP, Pedroso MLA, Pontarolo R. Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil. Rev Soc Bras Med Trop. 2020;53:e20190594.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"10","key":"700_CR37","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.21037\/apm-21-863","volume":"10","author":"HJ Zhou","year":"2021","unstructured":"Zhou HJ, Wu G, Li JM, Naidoo N, Xie YX, Feng BL, et al. Cost-effectiveness analysis of glecaprevir\/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection. Annals Palliat Med. 2021;10(10):10313\u201326.","journal-title":"Annals Palliat Med"},{"issue":"3","key":"700_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14737167.2019.1629291","volume":"20","author":"S Gordon","year":"2020","unstructured":"Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic hepatitis C in the united States. Expert Rev PharmacoEcon Outcomes Res. 2020;20(3):251\u20137.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"8","key":"700_CR39","doi-asserted-by":"publisher","first-page":"e035224","DOI":"10.1136\/bmjopen-2019-035224","volume":"10","author":"H Yun","year":"2020","unstructured":"Yun H, Zhao G, Sun X, Shi L. Cost-utility of sofosbuvir\/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open. 2020;10(8):e035224.","journal-title":"BMJ Open"},{"issue":"12","key":"700_CR40","first-page":"1352","volume":"18","author":"P Chen","year":"2018","unstructured":"Chen P, Li H, Ma A. Elbasvir\/grazoprevir for patients with chronic hepatitis C virus genotype 1b infection in china: an economic evaluation. Chin J Evidence-Based Med. 2018;18(12):1352\u20138.","journal-title":"Chin J Evidence-Based Med"},{"issue":"11","key":"700_CR41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40261-018-0702-9","volume":"38","author":"P Chen","year":"2018","unstructured":"Chen P, Ma A, Liu Q. Cost-Effectiveness of Elbasvir\/Grazoprevir versus Daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China. Clin Drug Investig. 2018;38(11):1031\u20139.","journal-title":"Clin Drug Investig"},{"key":"700_CR42","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.jval.2018.07.484","volume":"21","author":"PY Chen","year":"2018","unstructured":"Chen PY, Liu Q, Li HC, Ma AX. Cost-Effectiveness of Elbasvir\/Grazoprevir versus Ombitasvir\/Paritaprevir\/Ritonavir plus dasabuvir (3D Regimen) for treatment of chronic hepatitis C genotype 1B patients in China. Value Health. 2018;21:S64.","journal-title":"Value Health"},{"issue":"3","key":"700_CR43","doi-asserted-by":"publisher","first-page":"e0194329","DOI":"10.1371\/journal.pone.0194329","volume":"13","author":"F Maunoury","year":"2018","unstructured":"Maunoury F, Cl\u00e9ment A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, et al. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4\u20135 chronic kidney disease patients in France. PLoS ONE. 2018;13(3):e0194329.","journal-title":"PLoS ONE"},{"issue":"9","key":"700_CR44","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10198-018-0980-4","volume":"19","author":"FR Rolli","year":"2018","unstructured":"Rolli FR, Ruggeri M, Kheiraoui F, Drago C, Basile M, Favaretti C, et al. Economic evaluation of zepatier for the management of HCV in the Italian scenario. Eur J Health Economics: HEPAC : Health Econ Prev Care. 2018;19(9):1365\u201374.","journal-title":"Eur J Health Economics: HEPAC : Health Econ Prev Care"},{"key":"700_CR45","unstructured":"Shitik L. Cost-Utility analysis of Direct-Acting antiviral agents in Treatment-Na\u00efve patients with chronic hepatitis C virus genotype 1 infection 2018."},{"issue":"8","key":"700_CR46","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jval.2017.05.003","volume":"20","author":"S Corman","year":"2017","unstructured":"Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir\/Grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2017;20(8):1110\u201320.","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"4","key":"700_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jvh.12639","volume":"24","author":"E Elbasha","year":"2017","unstructured":"Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir\/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the united States. J Viral Hepatitis. 2017;24(4):268\u201379.","journal-title":"J Viral Hepatitis"},{"issue":"3","key":"700_CR48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/apt.13882","volume":"45","author":"EH Elbasha","year":"2017","unstructured":"Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-na\u00efve and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the united States. Aliment Pharmacol Ther. 2017;45(3):455\u201367.","journal-title":"Aliment Pharmacol Ther"},{"key":"700_CR49","doi-asserted-by":"crossref","unstructured":"Alowairdhi MA. The Cost-Effectiveness of treatments in Non-Cirrhotic Saudi Arabian patients with genotype 1 and genotype 4 chronic hepatitis. University of Toledo; 2017.","DOI":"10.1016\/j.jval.2018.04.570"},{"issue":"11","key":"700_CR50","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1177\/1060028017722007","volume":"51","author":"TJ Mattingly","year":"2017","unstructured":"Mattingly TJ 2nd, Slejko JF, Mullins CD. Hepatitis C treatment regimens are Cost-Effective: but compared with what? Annals Pharmacotherapy. 2017;51(11):961\u20139.","journal-title":"Annals Pharmacotherapy"},{"issue":"3","key":"700_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40121-024-00926-1","volume":"13","author":"E Warren","year":"2024","unstructured":"Warren E, Castles BJC, Sharratt GC, Arteaga A. Direct-Acting antivirals remain Cost-Effective treatments for chronic hepatitis C in Australia despite changes to the treated population and the availability of retreatment: the Glecaprevir\/Pibrentasvir (Maviret\u00ae) example. Infect Dis Ther. 2024;13(3):549\u201364. https:\/\/doi.org\/10.1007\/s40121-024-00926-1. Epub 2024 Mar 1. PMID: 38427290; PMCID: PMC10965868.","journal-title":"Infect Dis Ther"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00700-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:04:19Z","timestamp":1769785459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00700-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00700-1","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"25 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of previously published literature and did not involve any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}